Introducing the latest JUVÉDERM® innovation  >
EXPAND TO SEE ALL ALLERGAN BRANDS +
For Us Healthcare Professionals
Important Safety Information Patient Safety Information + Directions for use + FOR US PATIENTS Contact Us Set up Account
Product Information Training Practice resources Ordering Rewards Results

FOR US HEALTHCARE PROFESSIONALS

PRODUCT INFORMATION TRAINING PRACTICE RESOURCES ORDERING REWARDS RESULTS
Important Safety Information Patient Safety Information Directions for Use FOR US PATIENTS Contact Us Set Up Account
×
BOTOX® COSMETIC
(onabotulinumtoxinA)
KYBELLA®
(deoxycholic acid) injection 10 mg/ml
COOLSCULPTING®
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
NATRELLE®
SKINMEDICA®
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM® VOLUMA® XC
  • JUVÉDERM® VOLBELLA® XC for Lip Augmentation
  • JUVÉDERM® VOLBELLA® XC for Undereye Hollows
  • JUVÉDERM® VOLLURE® XC
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM® VOLUMA® XC
  • JUVÉDERM® VOLBELLA® XC
  • JUVÉDERM® VOLLURE® XC
Read More +
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS
The JUVÉDERM® Collection of Fillers includes JUVÉDERM VOLUMA™ XC, JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM VOLBELLA® XC. JUVÉDERM VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.
INTERESTED IN DOING BUSINESS WITH ALLERGAN AESTHETICS?
844-NEW-2AGN
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS AND IMPORTANT SAFETY INFORMATION
The JUVÉDERM® Collection of Fillers includes JUVÉDERM® VOLUMA® XC, JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM® VOLBELLA® XC. JUVÉDERM® VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit and for augmentation of the chin region to improve the chin profile in adults over the age of 21. JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM® VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.
JUVÉDERM® Collection of Fillers Important Information
INDICATIONS

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.


JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.


JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.


JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).


JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.
WARNINGS
•Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
•Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
PRECAUTIONS
•To minimize the risks of potential complications, this product should only be used by healthcare professionals with appropriate experience and training on facial anatomy and product use in indicated area(s), vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
•The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
•The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
•The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
•The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation and in patients between 22 and 80 years of age for chin augmentation
•The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
•As with all transcutaneous procedures, dermal filler implantation carries a risk of infection
•Dermal fillers should be used with caution in patients on immunosuppressive therapy
•Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
•Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
•If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
•The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
•The safety of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
•JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
•The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
•Patients may experience late-onset adverse events with use of these dermal fillers, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
•Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs) body mass per year. The safety of injecting greater amounts has not been established







ADVERSE EVENTS
The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA® XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA® XC, most resolved within 30 days.
To report an adverse reaction with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1 877 345 5372. Please visit JuvedermDFU.com for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-voluma-xc_dfu.pdf for JUVÉDERM® VOLUMA® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-vollure-xc_dfu.pdf for JUVÉDERM® VOLLURE® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-volbella_dfu.pdf for JUVÉDERM® VOLBELLA® XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf for JUVÉDERM® Ultra Plus XC
Please see Directions for Use or visit https://www.rxabbvie.com/pdf/juvederm-ultra-xc_dfu.pdf for JUVÉDERM® Ultra XC

Privacy Statement | California Privacy Policy | Terms of Use
JUVÉDERM®, VOLUMA®, VOLLURE®, VOLBELLA®, and their designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. © 2022 AbbVie. All rights reserved.
hcp.Juvederm.com JUV106549-v7 01/22 012613

This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). Read More By clicking "Accept" you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above. You can still use this website if you do not click "Accept," but your experience may be different. For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policyopens in a new window or for additional options please check your browser’s settings. Read Less

Accept
×